

Wrightington, Wigan and Leigh Teaching Hospitals

NHS Foundation Trust

Information Governance Department

Suite 9
Buckingham Row
Brick Kiln Lane
Wigan
WN1 1XX

Email: foi@wwl.nhs.uk

Web: www.wwl.nhs.uk

Ref: FOI/2025/11011

Date Received: 13th August 2025

Response Due: 11th September 2025

Date: 9th September 2025

Dear Sir/Madam

With reference to your request for information received on 13th August 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold part of the information you have requested. A response to each part of your request is provided below.

In your request you asked:

I would be grateful if you could tell me how many patients were treated by individual drug for Crohn's Disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis for the three-month period specified within the question.

I have provided a grid of drug names and disease names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Q1a – How many patients were treated with the following drugs for the following diseases from the start of April 2025 to the end of June 2025?

Please use the latest available 3 months if April to June is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	*Other patients (indication unknown)
Adalimumab	25	133	50	47	
Apremilast	0			2	3
Bimekizumab	32			6	
Brodalumab	0				

Certolizumab Pegol	2			5	
Deucravacitinib	3				
Etanercept	0			29	
Etrasimod			0		
Filgotinib			1		
Golimumab			0	10	
Guselkumab	54			1	
Infliximab (Biosimilars)	0	14	8	0	35
Infliximab (Remicade)	0	0	0	0	
Ixekizumab	1			1	
Mirikizumab			9		
Ozanimod			0		
Risankizumab	77	31	4	0	20
Secukinumab	23			26	
Tildrakizumab	3				
Tofacitinib			1	1	
Upadacitinib*		24	32	1	14
Ustekinumab*	22	91	38	3	39
Vedolizumab*		55	53		33

Time period = 1st April 2025 to 30th June 2025.

*Indication data is only available for the subset of patients that receive medication via homecare as the pharmacy systems for direct issue / issue under SLA do not record this. Where there are such patients from gastroenterology or dermatology that this applies to for a specific drug, this been added in the last column under '*Other Patients (indication unknown)'.

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Gary Masterman
Associate Director of Pharmacy (Governance Assurance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111